Tag: alexion pharmaceuticals

March 11, 2020

Analyst Lowers BridgeBio Price Target After Debt Issuance

George Farmer told investors that BMO Capital Markets is lowering its price target for BridgeBio Pharma to US$46, down from...
January 30, 2020

Alexion Reports Fourth Quarter and Full Year 2019 Results

Alexion Pharmaceuticals announced its financial results for the fourth quarter and its full fiscal 2019 year.
March 26, 2019

7 Potential Blockbuster Drugs Investors Should Watch for in 2019

A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by...
September 24, 2018

Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder

Alexion Pharmaceuticals (NASDAQ:ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris (eculizumab) in patients with anti-aquaporin-4 (AQP4)...
June 28, 2018

Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU

Alexion Pharmaceuticals (NASDAQ:ALXN) announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the...
February 26, 2018

Positive Regulatory News from Two Pharmaceutical Companies Triggers Share Price Increases

Investors and analysts are focusing on KemPharm and Achillion after both companies received recent positive regulatory news.
April 25, 2017

biOasis Technologies Appoints New CEO

biOasis Technologies announced the appointment of Dr. Mark Day as president and CEO of the company.